Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

OBJECTIVE: The SELECT‐EARLY trial was undertaken to study the effect of upadacitinib, an oral, reversible Janus kinase 1–selective inhibitor, as monotherapy in patients with predominantly early rheumatoid arthritis who were naive for or had limited exposure to methotrexate (MTX). METHODS: Patients (...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vollenhoven, Ronald, Takeuchi, Tsutomu, Pangan, Aileen L., Friedman, Alan, Mohamed, Mohamed‐Eslam F., Chen, Su, Rischmueller, Maureen, Blanco, Ricardo, Xavier, Ricardo M., Strand, Vibeke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589375/
https://www.ncbi.nlm.nih.gov/pubmed/32638504
http://dx.doi.org/10.1002/art.41384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589375/
https://www.ncbi.nlm.nih.gov/pubmed/32638504
http://dx.doi.org/10.1002/art.41384

Ejemplares similares